Clinical Evidence
The Science Behind GLIA's Research
GLIA Diagnostics has conducted human clinical studies investigating circulating microRNA biomarkers for traumatic brain injury. This page summarises the published evidence base and explains what the research does — and does not — currently support.
Why Clinical Evidence Matters in TBI Diagnostics
Traumatic brain injury (TBI) is one of the most clinically challenging conditions to assess objectively. Mild TBI — including concussion — frequently presents with normal CT and MRI findings, leaving clinicians reliant on symptom reporting and observational tools that are inherently subjective. The development of blood-based biomarkers represents a significant scientific effort to provide objective, biological evidence of brain injury at the point of care (PoC).
For any biomarker to be clinically useful, it must be supported by rigorous human clinical evidence — not just laboratory or animal data. GLIA Diagnostics has prioritised human clinical research from early in its development programme, conducting studies across sport, military, and civilian TBI populations. The peer-reviewed publications arising from this work form the foundation of GLIA's scientific credibility and IP position.
All findings described on this page are from published, peer-reviewed research. GLIA's diagnostic platform remains investigational. The research findings do not constitute regulatory clearance or clinical validation for diagnostic use.
Peer-Reviewed Research
Published Studies
The following publications represent peer-reviewed research from GLIA Diagnostics and its research collaborators. These studies are investigational. Findings do not constitute regulatory clearance or approval for clinical diagnostic use.
Mitra B et al.
Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study
A pilot study investigating plasma miRNA biomarkers for diagnosis and prognosis following traumatic brain injury. This foundational study identified candidate circulating miRNAs with potential utility as objective biological indicators of brain injury.
Pilot study — plasma miRNA diagnosis and prognosis after TBI
View publication →Mitra B et al.
Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study
A longitudinal cohort study examining the relationship between circulating miRNA levels and symptom profiles following mild TBI. The study tracked miRNA expression and symptom burden over time, exploring the potential of miRNA as a biological correlate of mTBI recovery.
Longitudinal cohort — miRNA levels and symptom profile after mTBI
View publication →Mitra B et al.
MicroRNA biomarkers for diagnosis of mild traumatic brain injury and prediction of persistent symptoms: A prospective cohort study
A prospective cohort study evaluating miRNA biomarkers for both diagnosis of mTBI and prediction of persistent post-concussive symptoms. The research examined whether early miRNA signals could identify patients at risk of prolonged recovery.
Prospective cohort — miRNA diagnosis of mTBI and prediction of persistent symptoms
View publication →Mitra B et al.
MicroRNA Biomarkers on Day of Injury Among Patients with Post Concussive Symptoms at 28-Days: A Prospective Cohort Study
A prospective cohort study examining day-of-injury miRNA biomarker levels in patients who subsequently developed post-concussive symptoms at 28 days. The study investigated whether acute miRNA signals could serve as early predictors of prolonged symptom burden.
Prospective cohort — day-of-injury miRNA and 28-day post-concussive symptoms
View publication →Interpreting the Evidence
What the Research Currently Supports
It is important to be precise about what GLIA's published research does and does not currently demonstrate. The following reflects an honest summary of the current evidence base.
What the research currently supports
- Circulating miRNAs can be detected in blood following TBI in human clinical populations, including sport, military, and civilian cohorts.
- Specific brain-enriched miRNAs show altered expression patterns following head injury compared to pre-injury or uninjured control measurements.
- A panel approach — measuring multiple miRNAs simultaneously — may provide complementary biological information compared to any single biomarker.
- Serial miRNA measurements over time show temporal patterns that may be relevant to biological recovery monitoring.
- The miRNA panel has been studied in populations where conventional imaging (CT, MRI) was normal, suggesting potential utility in mild TBI where current tools have limited sensitivity.
What the research does not yet support
- Regulatory clearance or approval for clinical diagnostic use in any jurisdiction. GLIA's platform is investigational.
- Established clinical sensitivity and specificity thresholds validated across diverse populations at the scale required for regulatory submission.
- Definitive claims about the cellular or anatomical origin of the miRNA signals detected.
- Validated prognostic or return-to-activity decision thresholds. These require further prospective clinical validation.
Scientific Context
TBI Biomarker Research: The Broader Landscape
TBI biomarker research has accelerated significantly over the past decade. Protein biomarkers — particularly GFAP (Glial Fibrillary Acidic Protein) and UCH-L1 (Ubiquitin C-terminal Hydrolase-L1) — have achieved regulatory milestones, with the Abbott i-STAT TBI test FDA-cleared for use in adults with suspected mTBI in emergency settings. S100B is widely used in Europe as a triage tool to guide CT imaging decisions.
MicroRNA biomarkers represent a distinct and complementary class of molecular signal. Unlike proteins, miRNAs are nucleic acids — small, non-coding RNA molecules that regulate gene expression. Their stability in blood (protected by encapsulation in exosomes and protein complexes), tissue-associated expression patterns, and potential sensitivity across a broader post-injury window have made them an active area of TBI biomarker research internationally.
GLIA's research contributes to a growing body of peer-reviewed literature on circulating miRNAs in TBI. The company's approach — studying a proprietary panel of brain-enriched miRNAs across multiple clinical populations — is designed to build the evidence base required for eventual regulatory submission and clinical translation.
Research Methodology
How GLIA's Studies Were Conducted
GLIA's clinical studies have been prospective in design, recruiting participants with documented or suspected TBI across sport, military, and civilian settings. Studies have included pre-injury baseline measurements where feasible (particularly in sport cohorts), enabling within-subject comparisons that reduce the confounding effects of inter-individual biological variability.
Blood samples have been collected at defined time points following injury, with longitudinal sampling in selected studies to characterise temporal miRNA profiles. Samples have been processed and analysed using validated molecular biology methods, with miRNA quantification performed using established platforms.
All studies have been conducted under appropriate ethical approvals and in accordance with relevant research governance frameworks. GLIA's research collaborators include academic institutions and clinical research groups with expertise in neurotrauma, sports medicine, and military medicine.
Explore the Science Further
Investigational Technology. Rigorous Science.
GLIA's diagnostic platform is not yet approved for clinical use. Our published research represents the scientific foundation for a technology that aims to change how TBI is assessed — in sport, defence, and clinical settings worldwide.